KLB, klotho beta, 152831

N. diseases: 53; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.320 GeneticVariation disease BEFREE <i>KLB</i> rs7674434 and rs12152703 had associations with alanine aminotransferase (ALT) (<i>P</i> = 0.03 and <i>P</i> = 0.04, respectively) and gamma-glutamyltransferase (<i>P</i> = 0.03 and <i>P</i> = 0.02, respectively) levels in all subjects, but the associations were especially strong with ALT in the NAFLD group (<i>P</i> = 0.005 and <i>P</i> = 0.008, respectively). 31548436 2019
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.320 Biomarker disease CTD_human Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. 29289645 2018
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.320 GeneticVariation disease BEFREE We evaluated the impact of the rs17618244 G>A β-Klotho (KLB) variant on liver damage in 249 pediatric patients with biopsy-proven NAFLD and the association of this variant with the expression of hepatic and soluble KLB. 31655133 2020
CUI: C3899503
Disease: Congenital hypogonadotropic hypogonadism
Congenital hypogonadotropic hypogonadism 		0.310 Biomarker disease GENOMICS_ENGLAND KLB, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. 28754744 2017
CUI: C3899503
Disease: Congenital hypogonadotropic hypogonadism
Congenital hypogonadotropic hypogonadism 		0.310 Biomarker disease GENOMICS_ENGLAND
CUI: C3899503
Disease: Congenital hypogonadotropic hypogonadism
Congenital hypogonadotropic hypogonadism 		0.310 GeneticVariation disease BEFREE <i>KLB</i>, encoding β-Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. 28754744 2017
CUI: C3241937
Disease: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis 		0.300 Biomarker disease CTD_human Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. 29289645 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.100 AlteredExpression disease BEFREE KLB and FGFR1 were upregulated in AT in relation to obesity, and both were further increased 12 months after RYGB. 28552744 2017
CUI: C0028754
Disease: Obesity
Obesity 		0.100 AlteredExpression disease BEFREE In addition to higher FGF21 levels, reduced KLB expression in liver and adipose tissue has been noted in these same individuals, suggesting that obesity may represent an FGF21 resistant state. 26901091 2016
CUI: C0028754
Disease: Obesity
Obesity 		0.100 AlteredExpression disease BEFREE Since obesity has been reported to be associated with reduced expression of FGFR1 and βKlotho receptor in white adipose tissues in mice, our results suggest that the distribution in adipose tissues was influenced by target expression levels. 28895785 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.100 Biomarker disease BEFREE However, further studies are needed to explore the possibility that Klotho could be a novel therapeutic target to reduce obesity and related complications, and to determine whether and how Klotho might influence the regulation and function of a related protein, β-Klotho, which is also involved in energy metabolism. 22641000 2012
CUI: C0028754
Disease: Obesity
Obesity 		0.100 Biomarker disease BEFREE Recent microRNA (miR) studies have revealed that aberrantly elevated miR-34a in obesity directly targets β-Klotho, the obligate coreceptor for both FGF19 and FGF21, and attenuates metabolic signaling of these hormones. 27125742 2016
CUI: C0028754
Disease: Obesity
Obesity 		0.100 Biomarker disease BEFREE These results indicate that aberrantly elevated miR-34a in obesity attenuates hepatic FGF19 signaling by directly targeting βKL. 22988100 2012
CUI: C0028754
Disease: Obesity
Obesity 		0.100 GeneticVariation disease BEFREE The G-allele frequency of <i>KLB</i> rs7674434 and T-allele frequency of rs12152703 were higher in the obese with NAFLD than obese without NAFLD group (<i>P</i> = 0.004 and <i>P</i> = 0.006), but the genotype distribution between two non-obese groups did not differ. 31548436 2019
CUI: C0028754
Disease: Obesity
Obesity 		0.100 Biomarker disease BEFREE Replenishment of recombinant FGF21 to a level equivalent to that in obesity restores SAT mass and reverses insulin resistance in FGF21KO, but not in adipose-specific βklotho knockout mice. 29348470 2018
CUI: C0028754
Disease: Obesity
Obesity 		0.100 AlteredExpression disease BEFREE In WAT, overweight/obesity with and without type 2 diabetes led to reduced expression of KLB, but increased FGFR1c expression. 28721439 2017
CUI: C0028754
Disease: Obesity
Obesity 		0.100 Biomarker disease BEFREE β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. 28422755 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.040 Biomarker disease BEFREE These data suggest βKlotho suppresses tumor growth in hepatocellular carcinoma. 23383245 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.040 Biomarker disease BEFREE Although it is well established that FGF19 acts through the receptor complex FGFR4-β-Klotho (KLB) to regulate bile acid metabolism, FGF19 is also implicated in the development of HCC. 24728076 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.040 Biomarker disease BEFREE The restricted tissue expression profile of KLB, together with the anti-proliferative effect observed with KLB-silencing, also qualifies it as a specific and potent therapeutic target for HCC patients. 22439738 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.040 AlteredExpression disease BEFREE Here we show that βklotho expression is more consistently down-regulated in human and mouse hepatomas than FGFR4. 20657013 2010
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.030 AlteredExpression disease BEFREE In WAT, overweight/obesity with and without type 2 diabetes led to reduced expression of KLB, but increased FGFR1c expression. 28721439 2017
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.030 AlteredExpression disease BEFREE Our findings indicate that serum Klotho levels were associated with the development of T2DM, and long-term control of blood glucose will be beneficial in ameliorating changes to α-Klotho and β-Klotho levels in patients with T2DM and complications. 30042059 2018
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.030 AlteredExpression disease BEFREE Serum levels of α-Klotho and β-Klotho are down-regulated in patients with T2DM. 27916483 2017
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 AlteredExpression disease BEFREE Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer. 23317273 2012